Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut?

Hickey MS, Pories WJ, MacDonald KG Jr, Cory KA, Dohm GL, Swanson MS, Israel RG, Barakat HA, Considine RV, Caro JF, Houmard JA.

Ann Surg. 1998 May;227(5):637-43; discussion 643-4.

2.
5.

Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.

Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI.

Metabolism. 2004 Nov;53(11):1454-61.

PMID:
15536601
6.
7.

[Reduced resistin levels in patients with type 2 diabetes mellitus].

Yang J, Li M, Wu CY, Wang H, Xu QS, Deng JY.

Zhonghua Yi Xue Za Zhi. 2003 Sep 10;83(17):1471-4. Chinese.

PMID:
14521723
8.
9.

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA.

Diabetes Care. 2000 Aug;23(8):1154-61.

10.

Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes.

Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP.

Ann Intern Med. 2005 Mar 15;142(6):403-11.

PMID:
15767618
11.

Leptin in type 2 diabetic or myotonic dystrophic women.

Gómez JM, Molina A, Fernández-Castañer M, Soler J.

Horm Metab Res. 2001 Apr;33(4):246-9.

PMID:
11383930
12.

Weight loss and leptin changes in individuals with type 2 diabetes.

Williams KV, Mullen M, Lang W, Considine RV, Wing RR.

Obes Res. 1999 Mar;7(2):155-63.

13.

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.

Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.

Clin Ther. 2004 Sep;26(9):1427-35.

PMID:
15531005
14.

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.

Diabetes Care. 1998 Aug;21(8):1288-94.

PMID:
9702435
16.

Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women.

Kopp HP, Krzyzanowska K, Möhlig M, Spranger J, Pfeiffer AF, Schernthaner G.

Int J Obes (Lond). 2005 Jul;29(7):766-71.

PMID:
15917853
17.

Insulin resistance in nondiabetic morbidly obese patients: effect of bariatric surgery.

Pereira JA, Lazarin MA, Pareja JC, de Souza A, Muscelli E.

Obes Res. 2003 Dec;11(12):1495-501.

18.

Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.

Herrmann BL, Berg C, Vogel E, Nowak T, Renzing-Koehler K, Mann K, Saller B.

Horm Metab Res. 2004 Jan;36(1):54-61.

PMID:
14983408
19.

Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release.

Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L.

Obesity (Silver Spring). 2008 Feb;16(2):298-305. doi: 10.1038/oby.2007.83.

20.

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.

Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P.

Metabolism. 2001 Jul;50(7):856-61.

PMID:
11436194

Supplemental Content

Support Center